These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18661190)

  • 1. The impact of the Medicare Part D prescription benefit on generic drug use.
    Zhang JX; Yin W; Sun SX; Alexander GC
    J Gen Intern Med; 2008 Oct; 23(10):1673-8. PubMed ID: 18661190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impacts of generic competition and benefit management practices on spending for prescription drugs: evidence from Medicare's Part D benefit.
    Sheingold S; Nguyen NX
    Medicare Medicaid Res Rev; 2014; 4(1):. PubMed ID: 24918023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug benefit changes under Medicare Advantage Part D: heterogeneous effects on pharmaceutical use and expenditures.
    Ettner SL; Steers WN; Turk N; Quiter ES; Mangione CM
    J Gen Intern Med; 2011 Oct; 26(10):1195-200. PubMed ID: 21710313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries: An Analysis From the Medicare Part D Database.
    Sumarsono A; Lalani HS; Vaduganathan M; Navar AM; Fonarow GC; Das SR; Pandey A
    JAMA Cardiol; 2021 Jan; 6(1):92-96. PubMed ID: 32902560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA; Walberg MP; Tong E; Tan F; Rummel AE; Woelfel JA; Carr-Lopez SM; Galal SM
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures.
    Yin W; Basu A; Zhang JX; Rabbani A; Meltzer DO; Alexander GC
    Ann Intern Med; 2008 Feb; 148(3):169-77. PubMed ID: 18180465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance program.
    Bishop CE; Ryan AM; Gilden DM; Kubisiak J; Thomas CP
    Health Serv Res; 2009 Jun; 44(3):1010-28. PubMed ID: 19291168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Higher Generic Drug Use and Medicare Part D Star Ratings: An Observational Analysis.
    Hohmann N; Hansen R; Garza KB; Harris I; Kiptanui Z; Qian J
    Value Health; 2018 Oct; 21(10):1186-1191. PubMed ID: 30314619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
    Socal MP; Bai G; Anderson GF
    JAMA Intern Med; 2019 Jun; 179(6):832-833. PubMed ID: 30882842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
    Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
    J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sending The Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less Than Generics?
    Dusetzina SB; Jazowski S; Cole A; Nguyen J
    Health Aff (Millwood); 2019 Jul; 38(7):1188-1194. PubMed ID: 31260351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of medicare part D plan features on use of generic drugs.
    Tang Y; Gellad WF; Men A; Donohue JM
    Med Care; 2014 Jun; 52(6):541-8. PubMed ID: 24824538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of Medicare part D prescription drug benefit program on generic drug prescription: A study in long-term care facilities.
    Jung C; Padman R; Anwar S
    Medicine (Baltimore); 2019 Aug; 98(32):e16646. PubMed ID: 31393363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G; Weiss RC
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States.
    Helmuth ME; Liu Q; Turenne MN; Park JM; Oguntimein M; Dutcher SK; Balkrishnan R; Sharma P; Zee J; Leichtman AB; Smith AR
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):421-430. PubMed ID: 30819667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.
    Fischer MA; Avorn J
    Health Serv Res; 2003 Aug; 38(4):1051-63. PubMed ID: 12968816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.